Ongoing studies and studies under planning


Lymphoma studies:
  1. National multicentre phase II study:
    Norwegian study in transformed B-cell lymphomas.
    Patient inclusion has been stopped, patients will be followed for additional three years, and molecular studies are being performed to elucidate biological prognostic factors.

  2. Sec. Nordic mantle cell lymphoma phase II study:
    Primary treatment with high dose therapy and purged/unpurged autologous stem cell transplantation (ASCT) including rituximab for induction and in-vivo purging and maintenance.
    The preliminary results from this study are very promising and will be presented orally at the annual Meeting of the American Sosiety of Hematology Dec 2004.
    The third Nordic mantle cell study will employ radio immunotherapy with a b-emitting Yttrium isotope linked to rituximab (Zevalinâ) as part of the conditioning regimen. NRH will take a primary responsibility for this study.

  3. NLG-T-01: A Nordic phase II study of peripheral T-cell lymphomas based on dose-intensive induction and high-dose consolidation with autologous stem cell rescue.
    Preliminary results of this first-line study will be presented at 9th International Conference on Malignant Lymphoma in Lugano, June 2005. A follow up study is under planning.

    Solid tumours:

  4. Phase III study:
    European randomised multicentre study in small cell lung cancer with high dose ICE (x 3) versus standard ICE. (European bone marrow transplantation group (EBMT))

  5. Phase III study:
    European randomised multicentre HDT study as upfront therapy in high-risk testicular cancer (EBMT).

  6. Phase II study:
    Italian/Scandinavian study of HDT in locally advanced or metastatic Ewing sarcoma.

Non-myeloablative allogeneic stem cell transplantation (NMT): See Immunotherapy

 
Nov 9, 2004 Page visits: 5331
Scroll to top